Lewis W. Coopersmith is an associate professor at Rider University and vice-president of Health Products Research.

The 340B spread mechanism permits covered entities to retain the difference between discounted acquisition cost and commercial or Medicare reimbursement, incentivizing revenue capture rather than ...

Exclusive ex-China rights extend to up to 10 partnered biosimilar programs, positioning Sandoz to shape development and registration strategy using early commercial and market-access input. Financial ...

Rohit Tripathi, VP of Industry Strategy at RELEX, discusses how pharmaceutical reshoring demands end-to-end capability not ...

Capital continues to flow toward clinical-stage and platform biotech companies, with a wave of new deals, partnerships, and ...

Pharmaceutical Executive releases its 2026 Top 50 company rankings, FDA grants Bristol Myers Squibb's Zenbexus accelerated ...

Accelerated approval allows iberdomide with daratumumab/hyaluronidase and dexamethasone for adults with RRMM after ≥1 line including a proteasome inhibitor and an ...

A changing of the guard atop Pharm Exec’s latest listing of the top biopharma Rx revenue producers reflects an industry being remade in real time, becoming as much a map of franchise quality and ...

A funding roundup covers new IPO and Series A raises across Silence Therapeutics, AbCellera, Beyang Therapeutics, and Remepy, Tyler Seville of ADVI examines the policy concerns building around the ...

Sentynl holds an exclusive U.S. commercialization option for AATD-LD, while securing global manufacturing rights; Mereo retains commercial rights outside the U.S. and leads Phase III execution.

President Trump signs an executive order shrinking the recommended childhood vaccine schedule from 18 diseases to 11, and calls for the MMR shot to be split into three separate injections. President ...

We have been telling ourselves a story about pharma communications for the past 20 years. The story goes like this: Global ...